Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
about
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisOptimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.STAT inhibitors for cancer therapy.Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet countsSensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in miceLow-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsCardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms.Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis.
P2860
Q24186554-BAE8FBC9-DE19-4F9A-AB0F-D7BB481DC825Q24201893-190CE9DB-9826-46F9-95AE-607479657999Q33411763-E05DDBD7-BD32-4C9C-B0B4-2DA04EA66683Q33644206-F0284D30-CD89-49E7-9648-2114D7D3B09BQ34612536-461FF5BE-9226-4A34-BDE0-7E24C7EEFD45Q36145016-60AEE240-4367-45A0-BE91-C541146EF5FCQ36232824-50C9B3B4-41F9-4605-80AF-691D841761F1Q36894603-134FDD71-A414-4341-8CD1-F15B7BAFE1E0Q37168138-A6264E6C-5197-4EE8-B775-2EAC732ADE99Q37715790-4E44E95B-452A-4EEC-91A7-385A18248011Q38164139-4A1B766A-AE97-44F6-81CD-47C78055637AQ41144530-8528D763-D257-4B2A-B2FD-9251FCAA0B06Q41519422-E76AE463-64BD-4B23-8136-536C256EF578Q42224651-A71395B0-DDC1-40D1-B9C2-CA59A1212EEFQ45060240-2327BC68-0C60-419F-B6B5-EA420A2EC294
P2860
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Splenomegaly in myelofibrosis- ...... l of Janus kinase 2 inhibitors
@en
type
label
Splenomegaly in myelofibrosis- ...... l of Janus kinase 2 inhibitors
@en
prefLabel
Splenomegaly in myelofibrosis- ...... l of Janus kinase 2 inhibitors
@en
P2093
P2860
P921
P356
P1476
Splenomegaly in myelofibrosis- ...... l of Janus kinase 2 inhibitors
@en
P2093
Ehab Atallah
Jasleen Randhawa
Radovan Vrhovac
P2860
P2888
P356
10.1186/1756-8722-5-43
P5008
P577
2012-08-01T00:00:00Z
P5875
P6179
1043860278